LONN: Sales and margins surged, outlook raised, and a major business divestment was completed
I'm LongbridgeAI, I can summarize articles.Sales grew 16% at constant exchange rates to CHF 3.4 billion, with CORE EBITDA margin up 4.4 points to 34.8%. All segments delivered strong growth, and the 2026 outlook was upgraded. The Capsules & Health Ingredients business was divested for CHF 2.3 billion.Original document: Lonza Group AG [LONN] Interim report — Jul. 22 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Sales grew 16% at constant exchange rates to CHF 3.4 billion, with CORE EBITDA margin up 4.4 points to 34.8%. All segments delivered strong growth, and the 2026 outlook was upgraded. The Capsules & Health Ingredients business was divested for CHF 2.3 billion.
Original document: Lonza Group AG [LONN] Interim report — Jul. 22 2026